2. GROUP COMPOSITION
  Basis of consolidation

(a) Subsidiaries

Subsidiaries are all entities (including structured entities) over which the Group has control. The Group controls an entity when the Group is exposed to, or has rights to, variable returns from its involvement with the entity and has the ability to affect those returns through its power over the entity. Subsidiaries are fully consolidated from the date on which control is transferred to the Group. They are deconsolidated from the date that control ceases.

Inter-company transactions, balances and unrealised gains on transactions between Group companies are eliminated. Unrealised losses are also eliminated. When necessary, amounts reported by subsidiaries have been adjusted to conform with the Group's accounting policies.

(b) Changes in ownership interests in subsidiaries without change of control

Transactions with non-controlling interests that do not result in loss of control are accounted for as equity transactions, i.e. transactions with the owners in their capacity as owners. The difference between fair value of any consideration paid and the relevant share acquired of the carrying value of net assets of the subsidiary is recorded in equity. Gains or losses on disposals to non-controlling interests are also recorded in equity.

When entering into a written put on a non-controlling interest, the initial liability is recognised at the present value of the expected settlement price with a corresponding adjustment to equity. Thereafter if the non-controlling interest continues to be recognised, the Group takes subsequent changes in the expected changes in the liability as an adjustment in profit or loss. The Group believes this is an appropriate accounting policy, because there is no clear guidance in IFRS Accounting Standards as to whether IFRS 9 or 10 should be applied to the presentation of the remeasurement of a liability.

(c) Associates and joint ventures

Investments in associates and joint ventures are accounted for using the equity method of accounting. Under the equity method, the investment is initially recognised at cost, and the carrying amount is increased or decreased to recognise the investor's share of the profit or loss of the investee after the date of acquisition. The Group's investment in associates and joint ventures includes goodwill identified on acquisition. Loans made to associates and joint ventures that are equity in nature are treated as part of the cost of the investment made.

Associates are all entities over which the Group has significant influence but not control, generally accompanying a shareholding of between 20% and 50% of the voting rights.

Investments in joint arrangements are classified as either joint operations or joint ventures depending on the contractual rights and obligations of each investor. The Group has assessed the nature of its joint arrangements and determined them to be joint ventures.

The Group's share of post-acquisition profit or loss is recognised in the income statement, and its share of post-acquisition movements in other comprehensive income is recognised in other comprehensive income with a corresponding adjustment to the carrying amount of the investment. The carrying amount of the investment is also adjusted for the Group's share of post-acquisition movements in other net assets.

The Group excludes equity-settled share-based payment charges from its share in profits or losses from associates and joint ventures. As a result, it does not recognise the corresponding attributable share of the related share-based payment reserve within equity.

The Group determines at each reporting date if there are any indicators which would require the Group to test whether the investment in the associate or joint venture is impaired. If this is the case, the Group calculates the amount of impairment as the difference between the recoverable amount of the associate or joint venture and its carrying value and recognises the amount adjacent to share of profit/(loss) from associates in the income statement. Any reversal of impairment losses is recognised in the income statement, to the extent that the recoverable amount subsequently increases.

Dilution gains and losses arising in investments in associates and joint ventures are recognised in the income statement.

If the ownership interest in an associate is reduced but significant influence is retained, only a proportionate share of the amounts previously recognised in other comprehensive income is reclassified to profit or loss where appropriate.

When the Group's share of losses in an associate or joint venture equals or exceeds its interests in the associate or joint venture (which includes any long-term interests that, in substance, form part of the Group's net investment in the associate or joint venture), the Group does not recognise further losses, unless it has incurred obligations or made payments on behalf of the associate or joint venture. Where an impairment is recognised in respect of an associate or joint venture, the Group's share of equity-accounted results reflect amortisation based on an adjusted impaired fair value.

2.1 Investments in and loans to associates and joint ventures
2.1.1 Summary of investments in and loans to Cell C, other associates and other joint ventures
Critical accounting judgements and assumptions

(a) Classification of significant joint arrangements

The Group exercises judgement in determining the classification of its joint arrangements.

(b) Assessment of investment in associates and joint ventures for impairment

An investment in an associate or joint venture is tested for impairment whenever events or changes in circumstances indicate that the carrying amount may not be recoverable.

The Group assesses at each reporting date whether such indicators exist. Similarly, the investment in an associate or joint venture is subsequently reassessed for indications of impairment loss previously recognised that may no longer exist. If there is an indication that an impairment loss has reversed, the Group is required to estimate the recoverable amount of the previously impaired investment. The impairment loss is reversed if the recoverable amount exceeds its carrying amount. The recoverable amounts of the investment in an associate or joint venture are determined based on value-in-use calculations. Where such calculations are performed, it would require the use of estimates.

(c) Classification of significant associates

The Group performs control assessments and determines the classification of its significant associates. Refer to note 2.2.1.

The Group holds the following investments in and loans to associates and joint ventures:

    Cost and share of reserves   Loans   Cost and share of
reserves and loans
    31 May 2025
R’000
  31 May 2024
R’000
  31 May 2025
R’000
  31 May 2024
R’000
  31 May 2025
R’000
  31 May 2024
R’000
Cell C Limited   1 701 197     3 245 909   2 359 065   4 947 106   2 359 065
Other associates   71 388   64 821   3 853   17 560   75 241   82 381
Other joint ventures   36 702   33 512     36 394   36 702   69 906
    1 809 287   98 333   3 249 762   2 413 019   5 059 049   2 511 352
Disclosed as:                        
– Non-current assets   1 809 287   98 333   1 302 614   1 967 246   3 111 901   2 065 579
– Current assets       1 947 148   445 773   1 947 148   445 773

Loans to associates and joint ventures

        Total loans Current Non-current
  Effective
shareholding
Payable Interest
rate
2025 
R’000 
2024 
R’000 
2025 
R’000 
2024 
R’000 
2025 
R’000 
2024 
R’000 
Cell C Limited1 70.00% 3 3 3 245 909  2 359 065  1 943 295  424 490  1 302 614  1 934 575 
Blu Train Proprietary Limited2 64.68% On
demand
Linked
to prime
—  13 171  —  —  —  13 171 
I Talk Financial Services Proprietary Limited 30.38% On
demand
0% —  3 997  —  3 997  —  — 
I Talk Holdings Proprietary Limited 40.50% On
demand
Linked
to prime
—  19 500  —  —  —  19 500 
Mobii Systems Proprietary Limited 29.90% On
demand
0% 3 853  4 394  3 853  4 394  —  — 
Mobile Macs Proprietary Limited 50.00% On
demand
Prime +
2%
—  12 189  —  12 189  —  — 
T3 Telecoms SA 50.00% On
demand
0% —  703  —  703  —  — 
        3 249 762  2 413 019  1 947 148  445 773  1 302 614  1 967 246 
1 Refer to note 2.2.1 for details on the control assessment of Cell C Limited. Refer to note 3.2.1 for details of the treatment of the loans.
2 The Group does not control Blu Train, as it does not control the Board of Directors due to having only one of the two Directorships, and a minority shareholders vote.
3 Refer to the "Loans receivable from Cell C" table on the following page.

All loans with an on-demand feature approximate fair value.

Loans receivable from Cell C

    Debt 
funding 
2025 
R’000 
Reinvestment 
instrument 
2025 
R’000 
Deferral 
loan 
2025 
R’000 
Acquired 
loan 
claim 
2025 
R’000 
Total 
2025 
R’000 
Opening balance as at 1 June 2024   1 464 334  186 294  708 437  —  2 359 065 
Loan advanced   —  —  —  408 171  408 171 
Interest accrued   540 679  69 420  77 506  21 590  709 195 
Interest payments received   (188 278) (20 270) (77 506) (21 590) (307 644)
Capital payments received   —  —  (226 103) (4 513) (230 616)
Expected credit loss adjustment   249 990  20 676  23 313  13 759  307 738 
Closing balance as at 31 May 2025   2 066 725  256 120  505 647  417 417  3 245 909 
Credit-adjusted effective interest rate (%)   31.251 31.82 12.673 25.294  

Acquired loan claim

On 11 November 2024, TPC and Gramercy concluded a binding term sheet in terms of which TPC agreed to acquire a certain Claim of R463.6 million (including accrued interest), which Gramercy had against Cell C, for a purchase consideration of R450 million.

1 Interest on this loan is being recognised using a credit-adjusted effective interest rate of 31.25%. The credit-adjusted effective interest rate reflects the initial estimate of lifetime expected credit losses. This means that TPC will only recognise the cumulative changes (both favourable and unfavourable) in the initial estimate of lifetime expected credit losses as a loss allowance.
2 Interest on this loan is being recognised using a credit-adjusted effective interest rate of 31.8%. The credit-adjusted effective interest rate reflects the initial estimate of lifetime expected credit losses. This means that TPC will only recognise the cumulative changes (both favourable and unfavourable) in the initial estimate of lifetime expected credit losses as a loss allowance.
3 Interest on this loan is being recognised using a credit-adjusted effective interest rate of 12.67%. The credit-adjusted effective interest rate reflects the initial estimate of lifetime expected credit losses. This means that CEC will only recognise the cumulative changes (both favourable and unfavourable) in the initial estimate of lifetime expected credit losses as a loss allowance.
4 Interest on this loan is being recognised using a credit-adjusted effective interest rate of 25.29%. The credit-adjusted effective interest rate reflects the initial estimate of lifetime expected credit losses. This means that TPC will only recognise the cumulative changes (both favourable and unfavourable) in the initial estimate of lifetime expected credit losses as a loss allowance. Refer to note 3.4 for further information.
Investment in
Principal activity
Country of incorporation
  Associate
Cell C Limited
Network provider
South Africa
  Other associates*   Other joint ventures*   Total
    31 May 2025 
R’000 
  31 May 2024 
R’000 
  31 May 2025 
R’000 
  31 May 2024 
R’000 
  31 May 2025 
R’000 
  31 May 2024 
R’000 
  31 May 2025 
R’000 
  31 May 2024 
R’000 
Cost and share of reserves                                
Cost and share of reserves at the beginning of the year   —    —    64 821    58 731    33 512    24 454    98 333    83 185 
Share of (losses)/profits from associates and joint ventures   (98 653)3   —    22 240    6 358    21 037    9 058    (55 376)   15 416 
Share of (losses)/profits after tax   (69 278)   —    22 240    6 358    21 037    9 058    (26 001)   15 416 
Amortisation of intangible assets   (102 739)   —    —    —    —        (102 739)   — 
Deferred tax on the amortisation of intangible assets   73 364    —    —    —    —        73 364    — 
Foreign currency translation reserve   —    —    538    (268)   —    —    538    (268)
Dividends received   —    —    (13 372)   —    —    —    (13 372)   — 
Disposal of joint venture   —    —    —    —    (17 847)   —    (17 847)   — 
Additional investment   241 2292   —    740    —    —    —    241 969    — 
Reversal of impairment of investment in associate   1 558 621    —    (3 579)   —    —    —    1 555 042    — 
Cost and share of reserves at the end of the year   1 701 197    —    71 388    64 821    36 702    33 512    1 809 287    98 333 
Loans to associates and joint ventures                                
Loans at the beginning of the year   2 359 065    2 110 982    17 560    9 282    36 394    34 783    2 413 019    2 155 047 
Loans advanced to associates and joint ventures1   1 117 366    701 682    488    13 399    28 773    51 369    1 146 627    766 450 
Loans repaid by associates and joint ventures   (538 260)   (332 387)   (14 397)   (5 318)   (29 476)   (48 719)   (582 133)   (386 424)
Loans waived   —    —    —    —    (23 496)   —    (23 496)   — 
Expected credit loss   307 738    (121 212)   202    197    (12 195)   (1 039)   295 745    (122 054)
Loans at the end of the year   3 245 909    2 359 065    3 853    17 560    —    36 394    3 249 762    2 413 019 
Closing net book value   4 947 106    2 359 065    75 241    82 381    36 702    69 906    5 059 049    2 511 352 
* The Group has interests in a number of individually immaterial associates and joint ventures that are accounted for using the equity method which are aggregated under “other associates” and "other joint ventures".
1 Loans advanced to associates and joint ventures includes the interest accrued on existing loans.
2

In 2022, a debt owed by Cell C to a lessor was transferred to a newly established special purpose vehicle (SPV5) in exchange for a 10% shareholding in Cell C, which remains SPV5's sole asset. Blue Label issued a guarantee in favour of the lessor for the repayment of this debt, while TPC committed to providing R275 million ("repayment amount") in funding to SPV5 in exchange for a claim of R699 million in SPV5, enabling it to meet its repayment obligations. The debt will be settled in tranches over the period from 31 December 2024 to 31 December 2026.

On 31 December 2024, TPC advanced the first tranche of funding amounting to R100 million and was recognised as part of the investment cost. The remaining funding commitments are scheduled as follows:

  • R100 million on 31 December 2025;
  • R50 million on 31 December 2026; and
  • An additional R25 million on 31 December 2026, contingent upon the occurrence of certain liquidity events.

SPV5 is required to repay TPC for the amounts advanced from any future sale of shares or from dividends earned thereon, along with an additional R424 million plus 50% of the fair value of its 10% shareholding in Cell C, to the extent that the proceeds exceed R699 million. Since SPV5's only asset is its shareholding in Cell C, the repayment will be dependent on the disposal of these shares and/or dividends earned thereon. As a result, as of 31 December 2024, TPC has effectively acquired an additional 10% economic interest in Cell C, capped at the repayment amount. This investment will be equity accounted, subject to the cap, alongside TPC's existing 60% economic interest in Cell C. SPV5 is precluded from selling the Cell C shares without TPC's consent, but TPC has no rights with respect to directing the voting rights attached to the shares. In the event of default, TPC would be able to acquire the 10% shareholding in Cell C in settlement of its loan, but only with the prior approval of the Competition Commission of South Africa, as such acquisition would result in TPC acquiring control of Cell C.

TPC's loan commitment to SPV5, which has been accounted for as a derivative liability (carrying a value of R7 million as of 30 November 2024 and 31 December 2024, respectively), was derecognised on 31 December 2024 and reclassified as part of the acquisition cost of the additional investment in Cell C. The present value of the remaining funding obligations to SPV5, amounting to R148 million as of 31 December 2024, was recognised as part of the investment cost, with a corresponding liability recorded to SPV5.

3 The share of profits of R1.5 billion were offset against historic losses of R1.6 billion, resulting in a net loss recognised in the current year of R99 million. Refer to note 2.2 for further details.